Axiogenesis Cor.At mESC cardiomyocytes

Monday, 21 June, 2010 | Supplied by: Capsugel Australia Pty Ltd

Axiogenesis Cor.At mESC cardiomyocytes

Embryonic stem cell-derived cardiomyocytes have many of the phenotypic properties of primary cardiomyocytes and show great potential to model human diseases. The Cor.At cells are cardiomyocytes derived from transgenic mouse embryonic stem cells and are available cryopreserved in ampoules.

The cells are highly pure with ampoules containing 99% cardiomyocytes. Their minimal lot-to-lot variation is claimed to give consistent performance and the standardised production process ensures stable supply.

The cardiomyocytes are a good predictive model with relevant background including all important ion channels well characterised.

They are suitable for applications including: electrophysiology (patch clamp, microelectrode arrays, Ca2+ flux analysis), non-arrhythmic cardiotoxicity (cell viability, label-free analysis, troponin release), drug profiling and target discovery (hypertrophy, gene expression, transfection, tissue engineering).

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Cayman Chemical Kinase Screening Library (96-Well)

Cayman Chemical's Kinase Screening Library (96-Well) consists of two plates and contains...

AdipoGen Life Sciences GLP-1, GIP and GCG receptor agonists

AdipoGen's range of GLP-1, GIP and GCG receptor agonists includes Liraglutide, Retatrutide,...

Integrated DNA Technologies xGen Hybridization and Wash v3 Kit

Integrated DNA Technologies (IDT) has unveiled its xGen Hybridization and Wash v3 Kit — a...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd